Astellas and Pantherna to work together on mRNA-based medicine through direct reprogramming
Astellas Pharma Inc. and Pantherna Therapeutics GmbH have entered into a new technology evaluation agreement…
October 4, 2022 - 2 minutes
mRNA: A New Technology Moving into the Mainstream
Messenger RNA (mRNA) technology is based on the idea that human cells can be used as on-demand factories to develop therapeutic proteins by giving them instructions in the form of mRNA. Although mRNA therapeutics and vaccines could be found in drug development pipelines before Covid-19 emerged, the pandemic suddenly moved the mRNA technology into the limelight.
Now, the world has seen mass vaccinations using mRNA-based vaccines developed by Moderna and Pfizer/BioNTech. But the mRNA technology holds promise for other indications as well, including cancer and rare diseases. Read on to learn how this new technology is moving into the mainstream with an influx of investments and new discoveries.
Show More
Editor's Picks for mRNA technology
- Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?
- The COVID-19 pandemic has driven RNA therapeutics into the mainstream
- EMA Greenlights BioNTech and Pfizer mRNA Vaccine for Covid-19
- Next-Generation mRNA Vaccine Technology Unveiled in Series A Round
- Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology
European Biotech Industry Report 2021
This report discusses how the Covid-19 pandemic impacted Europe’s life science industry and covers recent market trends, investments, and collaborations.
Go to ReportLatest mRNA technology Articles
Canada injecting $11.1M into mRNA vaccine technology at University of British Columbia
The Canadian government is providing more than C$11.1 million (US$8.1 million) for two new mRNA…
October 3, 2022 - 2 minutes
Global consortium looks to develop breakthrough RNA-based anti-cancer immunotherapy
The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, Israel,…
September 19, 2022 - 2 minutes
Capstan Therapeutics launches with $165M to deliver on in vivo cell engineering
Capstan Therapeutics, Inc. has launched today with $165 million in financing to combine cell therapy…
September 14, 2022 - 3 minutes
Benchling launches solution to boost mRNA and RNA therapeutics development
Benchling has launched what it says is the industry’s first full set of capabilities for…
September 7, 2022 - 3 minutes
Lonza and Touchlight collaboration will expands customer’s access to DNA
Manufacturing partner, Lonza, has today (September 6) announced a collaboration with Touchlight, a biotech company…
September 6, 2022 - 2 minutes
Potential new cancer treatment target discovered by researchers in Sweden
A previously unknown mechanism that can control tumor growth in cultured cells and mice has…
August 30, 2022 - 2 minutes
Strategic collaboration announced in China to accelerate the development of bacterial drugs
A strategic cooperation between Porton Advanced Solutions and Suzhou Royaltech Med Co., Ltd was announced…
August 29, 2022 - 2 minutes
Millions in funding and new board members for Belgian mRNA company
The mRNA technologies company eTheRNA has raised €39 million ($38.7 million) in series B2 financing.…
August 24, 2022 - 3 minutes
IVI and Moderna sign MOU for vaccine R&D
The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and…
July 20, 2022 - 2 minutes
Cancer therapeutics company’s double win with $25M funding, and appointment of new board member
An mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of…
July 8, 2022 - 3 minutes
Exyte Builds mRNA Competence Center for WACKER in Germany
A messenger ribonucleic acid (mRNA) competence center is being built at the Halle Biotech site…
July 6, 2022 - 4 minutes
